In the US, atrial fibrillation (AF) affects up to 1 in 3 people in their lifetime and was estimated to affect approximately 10.55 mil-lion (95% CI, 10.48-10.62 million) people by 2019.1-3 Signifi-cant complications associated with AF include ischemic stroke, heart failure (HF), myocardial infarction, chronic kidney disease, demen-tia, and mortality. Oral anticoagulants (OACs) have reduced rates of stroke and mortality in patients with AF.4 This review summarizes current evidence regarding the epidemiology, pathophysiology, di-agnosis, and management of AF (Box).